Combining antibodies to eliminate NHL

A Stanford University School of Medicine team has found a way to boost the efficacy of blockbuster non-Hodgkin's lymphoma drug Rituxan rituximab

by combining the anti-CD20 antibody with mAbs against CD47.¹ The group thinks the combination could elicit fewer side effects than Rituxan plus chemotherapy, which is standard care for the blood cancer...